Intellectus Partners LLC raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,960 shares of the life sciences company’s stock after buying an additional 109 shares during the period. Illumina comprises approximately 1.1% of Intellectus Partners LLC’s investment portfolio, making the stock its 16th biggest position. Intellectus Partners LLC’s holdings in Illumina were worth $2,422,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of ILMN. Cim Investment Mangement Inc. boosted its stake in Illumina by 3.9% in the 2nd quarter. Cim Investment Mangement Inc. now owns 2,383 shares of the life sciences company’s stock worth $877,000 after purchasing an additional 89 shares during the period. Copper Rock Capital Partners LLC acquired a new stake in shares of Illumina during the 2nd quarter valued at $10,888,000. Arjuna Capital acquired a new stake in shares of Illumina during the 2nd quarter valued at $269,000. Handelsbanken Fonder AB boosted its stake in shares of Illumina by 45.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock valued at $22,329,000 after buying an additional 19,000 shares during the period. Finally, Keudell Morrison Wealth Management acquired a new stake in shares of Illumina during the 2nd quarter valued at $1,483,000. Hedge funds and other institutional investors own 90.90% of the company’s stock.
A number of brokerages have issued reports on ILMN. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a research note on Friday, September 13th. Canaccord Genuity lowered shares of Illumina from a “buy” rating to a “hold” rating and decreased their target price for the company from $330.00 to $300.00 in a research note on Tuesday, July 30th. Piper Jaffray Companies set a $348.00 target price on shares of Illumina and gave the company a “buy” rating in a research note on Friday, September 27th. Cowen decreased their target price on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research note on Friday, July 12th. Finally, ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $330.92.
In related news, SVP Oene Mark Van sold 625 shares of Illumina stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $304.84, for a total value of $190,525.00. Following the transaction, the senior vice president now owns 14,209 shares in the company, valued at approximately $4,331,471.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Monday, July 15th. The stock was sold at an average price of $302.04, for a total transaction of $3,020,400.00. Following the completion of the transaction, the senior vice president now owns 86,776 shares in the company, valued at approximately $26,209,823.04. The disclosure for this sale can be found here. Insiders have sold a total of 47,099 shares of company stock worth $13,897,460 in the last 90 days. 0.38% of the stock is owned by insiders.
Shares of Illumina stock traded up $7.72 during midday trading on Friday, reaching $305.90. 10,065 shares of the company’s stock traded hands, compared to its average volume of 1,028,585. The company has a market cap of $42.39 billion, a price-to-earnings ratio of 53.58, a price-to-earnings-growth ratio of 2.87 and a beta of 1.07. The company’s 50 day simple moving average is $291.13 and its 200 day simple moving average is $312.97. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.10 and a current ratio of 6.79. Illumina, Inc. has a 52 week low of $263.30 and a 52 week high of $380.76.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. Illumina’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.43 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 6.04 earnings per share for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: The Structure of a Futures Contract
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.